MaaT Pharma SA

MaaT Pharma is a clinical-stage biotechnology company headquartered in Lyon, France, dedicated to developing innovative gut microbiome-driven therapies. Its core mission is to develop, commercialize, and license pioneering microbiome medicines to improve survival outcomes for patients with severe oncology diseases through immune modulation.

The company's product pipeline centers on Microbiome Ecosystem Therapies (MET), including lead candidates MaaT013 (Xervyteg®), MaaT033, and MaaT034. MaaT013 is a high-diversity, donor-derived therapy in a pivotal Phase 3 trial for acute Graft-versus-Host Disease (aGvHD). MaaT033 aims to enhance survival in patients undergoing allogeneic hematopoietic stem cell transplantation and is also being explored for neurodegenerative conditions like ALS. MaaT034 is a co-cultured product designed to optimize responses to immune checkpoint inhibitors in solid tumors. MaaT Pharma leverages its proprietary AI-powered drug discovery platform, gutPrint®, and operates Europe's largest manufacturing facility for microbiome-based drugs.

Recent notable developments include positive topline results from the Phase 3 ARES study for MaaT013 in January 2025, demonstrating a 62% gastrointestinal response rate at day 28. Following this, a Marketing Authorization Application (MAA) for MaaT013 (Xervyteg®) was submitted to the European Medicines Agency (EMA) in June 2025, with feedback anticipated in mid-2026. MaaT Pharma, led by CEO and co-founder Hervé Affagard, also secured €37.5 million in financing from the European Investment Bank in July 2025 and entered a commercial agreement with Clinigen to facilitate European market access. The company was included in the CAC Small, CAC Mid & Small, and CAC All-Tradable indices in September 2025.